Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics disclosed its provisional Q4 2025 consolidated revenue of KRW 1.29T and operating profit of KRW 528.3B, bringing its full-year 2025 cumulative revenue to KRW 4.56T, up 30.3% year-on-year.
📊 [Key Disclosure Details & Financial Figures]
- Category: Provisional Operating Performance (Fair Disclosure) based on Consolidated Financial Statements
- Performance Periods:
- Current Period (Q4 2025): October 1, 2025 – December 31, 2025
- Prior Period (Q3 2025): July 1, 2025 – September 30, 2025
- Prior Year Same Period (Q4 2024): October 1, 2024 – December 31, 2024
- Cumulative Period (FY2025): January 1, 2025 – December 31, 2025
- Q4 2025 Performance (Original KRW units):
- Revenue: KRW 1,285,706,000,000 (KRW 1.29T / QoQ: +2.2%, YoY: +35.3%)
- Operating Profit: KRW 528,251,000,000 (KRW 528.3B / QoQ: -16.6%, YoY: +67.8%)
- Profit Before Tax: KRW 574,579,000,000 (KRW 574.6B / QoQ: -13.3%, YoY: +59.4%)
- Net Profit: KRW 453,050,000,000 (KRW 453.1B / QoQ: -8.7%, YoY: +74.1%)
- Net Profit Attributable to Owners of Parent: KRW 453,050,000,000 (KRW 453.1B / QoQ: -8.7%, YoY: +74.1%)
- FY2025 Full-Year Cumulative Performance (Original KRW units):
- Revenue: KRW 4,556,972,000,000 (KRW 4.56T / YoY: +30.3%)
- Operating Profit: KRW 2,069,221,000,000 (KRW 2.07T / YoY: +56.6%)
- Profit Before Tax: KRW 2,118,631,000,000 (KRW 2.12T / YoY: +53.0%)
- Net Profit: KRW 1,614,330,000,000 (KRW 1.61T / YoY: +55.2%)
- Net Profit Attributable to Owners of Parent: KRW 1,614,330,000,000 (KRW 1.61T / YoY: +55.2%)
- Information Provision Details: Provided by IR Team to domestic and foreign investors and press on January 21, 2026 at 16:30 KST
- Other Important Matters:
- Figures are preliminary prepared prior to the completion of the external audit and are subject to change.
- Stated figures exclude discontinued operations profit/loss from Samsung Bioepis following the corporate spin-off (Samsung Bioepis discontinued operations net profit: Q4 2024: KRW 61.24B; FY2024 Cumulative: KRW 43.01B; Q3 2025: KRW 78.08B; Q4 2025: KRW 56.90B; FY2025 Cumulative: KRW 170.02B).
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Comparing Preliminary Quarterly Figures with Final Statements in Audit Report
This disclosure provides preliminary operating results prior to the completion of external auditing, meaning financial figures may undergo adjustments upon audit finalization.
Tracking whether any differences arise between these provisional figures and the finalized numbers in the upcoming audit report is crucial for verifying the ultimate accuracy of the financial results.
Finalized details can be verified in upcoming annual business reports and audit report disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
